Can two immune boosters outsmart Chemo-Resistant colon cancer?
NCT ID NCT07729605
First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time
Summary
This phase 3 trial is testing whether adding two immune-boosting drugs, iparomlimab and tuvonralimab, to standard chemotherapy can help people with a specific type of metastatic colorectal cancer that has stopped responding to first-line treatment. The study includes about 270 adults whose tumors are microsatellite stable (MSS), a form that typically does not respond well to immunotherapy alone. Researchers are measuring whether the combination extends the time before the cancer grows again, and also tracking overall survival, tumor shrinkage, and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a combination of chemotherapy (FOLFIRI), bevacizumab, and two immune checkpoint inhibitors (iparomlimab and tuvonralimab)
- What this could lead to
- If successful, this could offer a new second-line treatment option for people with a common type of metastatic colorectal cancer that has not responded to initial therapy.
- What could go wrong
- This is an early-phase trial, so the added benefit of the immune drugs is unproven. Immune checkpoint inhibitors can cause serious side effects, and the combination may not improve survival.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The sixth affiliated hospital of Sun Yat-sen University
Guangzhou, Guangdong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smart drug home in on Hard-to-Treat cancers?
- Can a vaccine boost immunotherapy against a stubborn cancer?
- What does recovery really look like after aggressive peritoneal cancer surgery?
- Chemo holidays put to the test: can scheduled breaks beat continuous treatment for advanced colorectal cancer?
- Can a Two-Pronged attack shrink Hard-to-Treat colorectal tumors?
- Can a Two-Drug attack shrink Hard-to-Treat colorectal tumors?